EVAX

AI MemoPost-earnings T+3

Evaxion A/S

As of 2026-08-25/Post-earnings T+3/Confidence low

Open ticker Back to Memos

Data freshness

AI Memo

As of 2026-08-25 • Model: RankAlpha Sentiment Codex

Decision Panel

Action, confidence, horizon, and decision blockers at a glance.

Action

—

Confidence

low

Horizon

—

Key catalyst

Q2 2026 results were in line and runway remains into H2 2027 • 2026-08-20

Base target: $3 / p=55% prob

Biggest risk

EVAX remains pre-revenue, loss-making, and dependent on clinical and preclinical execution. EVX-01 data may disappoint on durability, EVX-04 and EVX-05 remain early, partnership discussions have not produced a disclosed deal, and future capital needs could create dilution risk.

Invalidation

Break below $2 or thesis failure.

What would change my mind?

The Q2 update improved the setup modestly: cash runway extends into H2 2027, EVX-01 three-year data is scheduled for October, EVX-04 is moving toward a clinical filing, and EVX-05 broadens the pipeline. Positive data or a partnership could be disproportionately meaningful at the current micro-cap valuation.

Research note

Recommendation

—

Confidence

low

As of

2026-08-25

Base target

p=55%

Bull target

p=25%

Bear target

p=20%

Key bullets

Fast scan of bull, bear, and watch items

BullKey bullets

Partnership or licensing announcement
The Q2 update improved the setup modestly: cash runway extends into H2 2027, EVX-01 three-year data is scheduled for October, EVX-04 is moving toward a clinical filing, and EVX-05 broadens the pipeline.
Positive data or a partnership could be disproportionately meaningful at the current micro-cap valuation.

BearKey bullets

Cash declined to $14.0 million by June 30, 2026; additional financing or partnering may eventually be required.
EVX-01 three-year data may fail to confirm durable efficacy or may be poorly received by the market.
EVX-04 remains preclinical and its planned regulatory filing could be delayed or require additional work.

WatchKey bullets

Q2 2026 results were in line and runway remains into H2 2027

Summary

High-level snapshot

Recommendation

Model confidence

low

Timeframe

Asset

Equity

Trigger

Post-earnings T+3

Base case: $3 (p=55%)

Target spread vs base: +62% / -35%

Scenario probabilities

Bull Target: $6 (p=25%)Base Target: $3 (p=55%)Bear Target: $2 (p=20%)

Commentary

Post-earnings news tone is moderately constructive because results were in line, runway was maintained, and the pipeline expanded. However, social sentiment, options data, short interest, employee data, analyst revisions, and verified market-reaction attribution are unavailable; zero values above should be read as unavailable rather than neutral observations. The deterministic prior turned positive after the earnings event, but evidence quality remains modest, uncertainty high, and peer benchmarking weak.

As of 2026-08-25 • Updated bi-weekly / post-earningsSource: Internal modelMethodology

Analyst Summary

Thesis highlights from the latest analysis

Bull Case

Bear Case

Drivers

Scannable catalysts and supporting factors

Partnership or licensing announcement

Scenarios

Bull Target (Scenario probability)

$6 / p=25% prob

Base Target (Scenario probability)

$3 / p=55% prob

Bear Target (Scenario probability)

$2 / p=20% prob

Analysis 2026-08-25 · RankAlpha Sentiment Codex

Analysis reference price unavailable. Targets are shown without scenario returns.

Sentiment & Exposure

News Sentiment (30d)

0.58

Social Sentiment (7d)

0.00

Events

Other notable items detected

EVENT2026-08-20
Q2 2026 results were in line and runway remains into H2 2027
Evaxion reported a $3.7 million Q2 net loss, $14.0 million of cash, and an unchanged operating runway into the second half of 2027. The print reduces near-term financing urgency but provides no confirmed analyst-revision or market-reaction signal [#PR-EARNINGS-2026-08-20] [#EARNINGS-TRANSCRIPT-2026Q2].
Prob 100.00% • Move 2.00% • Priced-in 80.00%
EVENT2026-11-23
Three-year EVX-01 data at ESMO
The company plans to present three-year clinical efficacy and durability data for personalized melanoma vaccine EVX-01 at the ESMO Congress in October. This is the clearest near-term binary value driver, but the evidence remains from a small-cap biotech with limited independent coverage [#PR-EARNINGS-2026-08-20] [#EARNINGS-TRANSCRIPT-2026Q2].
Prob 65.00% • Move 25.00% • Priced-in 40.00%
EVENT2026-12-31
EVX-04 regulatory filing target
Evaxion expects to submit the regulatory filing for clinical testing of its preclinical AML vaccine EVX-04 before year-end. Progress would support platform execution, but the program remains preclinical and timing is not guaranteed [#PR-EARNINGS-2026-08-20].
Prob 50.00% • Move 16.00% • Priced-in 25.00%

Short-term Catalysts

Next few weeks

No short-term catalysts

Long-term Catalysts

Months to a year

Partnership or licensing announcement
2026-12-31
Management reported several active partnership discussions around the AI-Immunology platform and pipeline, but no transaction has been announced. A signed collaboration could materially improve financing and validation prospects; continued delay would leave the thesis dependent on internal milestones [#PR-EARNINGS-2026-08-20] [#EARNINGS-TRANSCRIPT-2026Q2].
Prob 30% • Move 25% • Priced-in 15%

Risks

Cash declined to $14.0 million by June 30, 2026; additional financing or partnering may eventually be required.
EVX-01 three-year data may fail to confirm durable efficacy or may be poorly received by the market.
EVX-04 remains preclinical and its planned regulatory filing could be delayed or require additional work.
EVX-05 is an early preclinical glioblastoma program with unproven clinical translation.
No verified post-earnings analyst revisions, target changes, or price-reaction attribution are available in the packet.
The packet does not support a sufficiently direct operating peer set, limiting relative valuation and benchmarking.

Peers

Symbol	Summary
AYTU	Same-sector micro-cap candidate supplied only by a market-cap screen; not supported as a direct operating or scientific peer. Retain only for broad capital-markets and event-volatility context.
ENLV	Same-sector micro-cap candidate with insufficient evidence of direct platform, indication, or development comparability to Evaxion. Use only as loose biotech risk context.
LGVN	Same-sector micro-cap candidate without a demonstrated direct operating match to Evaxion's vaccine platform. It is not decision-grade for relative valuation or clinical benchmarking.

Sources

Internal and external references used in this analysis

Model source: RankAlpha Sentiment Codex
Analysis date: 2026-08-25

Loading AI feed…

Symbol

Summary

AYTU

Same-sector micro-cap candidate supplied only by a market-cap screen; not supported as a direct operating or scientific peer. Retain only for broad capital-markets and event-volatility context.

ENLV

Same-sector micro-cap candidate with insufficient evidence of direct platform, indication, or development comparability to Evaxion. Use only as loose biotech risk context.

LGVN

Same-sector micro-cap candidate without a demonstrated direct operating match to Evaxion's vaccine platform. It is not decision-grade for relative valuation or clinical benchmarking.